JP5674824B2 - 改良されたカルシウム製剤 - Google Patents
改良されたカルシウム製剤 Download PDFInfo
- Publication number
- JP5674824B2 JP5674824B2 JP2012554958A JP2012554958A JP5674824B2 JP 5674824 B2 JP5674824 B2 JP 5674824B2 JP 2012554958 A JP2012554958 A JP 2012554958A JP 2012554958 A JP2012554958 A JP 2012554958A JP 5674824 B2 JP5674824 B2 JP 5674824B2
- Authority
- JP
- Japan
- Prior art keywords
- calcium
- composition
- formulation
- composition according
- saccharide
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 239000000203 mixture Substances 0.000 title claims description 59
- 239000011575 calcium Substances 0.000 title claims description 43
- 229910052791 calcium Inorganic materials 0.000 title claims description 43
- OYPRJOBELJOOCE-UHFFFAOYSA-N Calcium Chemical compound [Ca] OYPRJOBELJOOCE-UHFFFAOYSA-N 0.000 title claims description 24
- 238000009472 formulation Methods 0.000 title description 28
- 229960005069 calcium Drugs 0.000 claims description 42
- -1 calcium saccharide Chemical class 0.000 claims description 20
- 206010037660 Pyrexia Diseases 0.000 claims description 16
- 235000013336 milk Nutrition 0.000 claims description 16
- 239000008267 milk Substances 0.000 claims description 16
- 210000004080 milk Anatomy 0.000 claims description 16
- 238000011282 treatment Methods 0.000 claims description 12
- 159000000007 calcium salts Chemical class 0.000 claims description 11
- UXVMQQNJUSDDNG-UHFFFAOYSA-L Calcium chloride Chemical group [Cl-].[Cl-].[Ca+2] UXVMQQNJUSDDNG-UHFFFAOYSA-L 0.000 claims description 9
- 239000001110 calcium chloride Substances 0.000 claims description 9
- 229910001628 calcium chloride Inorganic materials 0.000 claims description 9
- 229960002713 calcium chloride Drugs 0.000 claims description 9
- SEQVSYFEKVIYCP-UHFFFAOYSA-L magnesium hypophosphite Chemical compound [Mg+2].[O-]P=O.[O-]P=O SEQVSYFEKVIYCP-UHFFFAOYSA-L 0.000 claims description 9
- 229910001381 magnesium hypophosphite Inorganic materials 0.000 claims description 9
- 239000004227 calcium gluconate Substances 0.000 claims description 8
- 229960004494 calcium gluconate Drugs 0.000 claims description 8
- 235000013927 calcium gluconate Nutrition 0.000 claims description 8
- NEEHYRZPVYRGPP-UHFFFAOYSA-L calcium;2,3,4,5,6-pentahydroxyhexanoate Chemical compound [Ca+2].OCC(O)C(O)C(O)C(O)C([O-])=O.OCC(O)C(O)C(O)C(O)C([O-])=O NEEHYRZPVYRGPP-UHFFFAOYSA-L 0.000 claims description 8
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims description 7
- FYYHWMGAXLPEAU-UHFFFAOYSA-N Magnesium Chemical compound [Mg] FYYHWMGAXLPEAU-UHFFFAOYSA-N 0.000 claims description 6
- OAICVXFJPJFONN-UHFFFAOYSA-N Phosphorus Chemical compound [P] OAICVXFJPJFONN-UHFFFAOYSA-N 0.000 claims description 6
- 239000008121 dextrose Substances 0.000 claims description 6
- 239000011777 magnesium Substances 0.000 claims description 6
- 229910052749 magnesium Inorganic materials 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 239000011574 phosphorus Substances 0.000 claims description 6
- 229910052698 phosphorus Inorganic materials 0.000 claims description 6
- 150000003839 salts Chemical class 0.000 claims description 6
- 241000282849 Ruminantia Species 0.000 claims description 5
- 235000000346 sugar Nutrition 0.000 claims description 5
- MKJXYGKVIBWPFZ-UHFFFAOYSA-L calcium lactate Chemical compound [Ca+2].CC(O)C([O-])=O.CC(O)C([O-])=O MKJXYGKVIBWPFZ-UHFFFAOYSA-L 0.000 claims description 3
- 239000001527 calcium lactate Substances 0.000 claims description 3
- 229960002401 calcium lactate Drugs 0.000 claims description 3
- 235000011086 calcium lactate Nutrition 0.000 claims description 3
- 229940078480 calcium levulinate Drugs 0.000 claims description 3
- HCAJEUSONLESMK-UHFFFAOYSA-N cyclohexylsulfamic acid Chemical compound OS(=O)(=O)NC1CCCCC1 HCAJEUSONLESMK-UHFFFAOYSA-N 0.000 claims description 3
- 239000007972 injectable composition Substances 0.000 claims description 3
- 150000008163 sugars Chemical class 0.000 claims description 3
- BCZXFFBUYPCTSJ-UHFFFAOYSA-L Calcium propionate Chemical compound [Ca+2].CCC([O-])=O.CCC([O-])=O BCZXFFBUYPCTSJ-UHFFFAOYSA-L 0.000 claims description 2
- 235000001465 calcium Nutrition 0.000 claims description 2
- VSGNNIFQASZAOI-UHFFFAOYSA-L calcium acetate Chemical compound [Ca+2].CC([O-])=O.CC([O-])=O VSGNNIFQASZAOI-UHFFFAOYSA-L 0.000 claims description 2
- 239000001639 calcium acetate Substances 0.000 claims description 2
- 235000011092 calcium acetate Nutrition 0.000 claims description 2
- 229960005147 calcium acetate Drugs 0.000 claims description 2
- YALMXYPQBUJUME-UHFFFAOYSA-L calcium chlorate Chemical compound [Ca+2].[O-]Cl(=O)=O.[O-]Cl(=O)=O YALMXYPQBUJUME-UHFFFAOYSA-L 0.000 claims description 2
- 235000010331 calcium propionate Nutrition 0.000 claims description 2
- 239000004330 calcium propionate Substances 0.000 claims description 2
- 238000001802 infusion Methods 0.000 claims 1
- 239000000243 solution Substances 0.000 description 24
- 241001465754 Metazoa Species 0.000 description 19
- ZOXJGFHDIHLPTG-UHFFFAOYSA-N Boron Chemical compound [B] ZOXJGFHDIHLPTG-UHFFFAOYSA-N 0.000 description 8
- 241000283690 Bos taurus Species 0.000 description 8
- 229910052796 boron Inorganic materials 0.000 description 8
- 238000007792 addition Methods 0.000 description 7
- DNIAPMSPPWPWGF-UHFFFAOYSA-N Propylene glycol Chemical compound CC(O)CO DNIAPMSPPWPWGF-UHFFFAOYSA-N 0.000 description 6
- 229940069978 calcium supplement Drugs 0.000 description 6
- 229960001031 glucose Drugs 0.000 description 6
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 6
- 239000008215 water for injection Substances 0.000 description 6
- LXCFILQKKLGQFO-UHFFFAOYSA-N methylparaben Chemical compound COC(=O)C1=CC=C(O)C=C1 LXCFILQKKLGQFO-UHFFFAOYSA-N 0.000 description 4
- 206010033799 Paralysis Diseases 0.000 description 3
- 238000003756 stirring Methods 0.000 description 3
- 238000012360 testing method Methods 0.000 description 3
- TWRXJAOTZQYOKJ-UHFFFAOYSA-L Magnesium chloride Chemical group [Mg+2].[Cl-].[Cl-] TWRXJAOTZQYOKJ-UHFFFAOYSA-L 0.000 description 2
- 239000000654 additive Substances 0.000 description 2
- 230000008901 benefit Effects 0.000 description 2
- WQZGKKKJIJFFOK-VFUOTHLCSA-N beta-D-glucose Chemical compound OC[C@H]1O[C@@H](O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-VFUOTHLCSA-N 0.000 description 2
- 229940072020 calcium borogluconate Drugs 0.000 description 2
- SSKRIDIHZLFJCG-UHFFFAOYSA-L calcium;2,3-dihydroxy-3-[2-hydroxy-5-(hydroxymethyl)-1,3,2-dioxaborolan-4-yl]propanoate Chemical compound [Ca+2].OCC1OB(O)OC1C(O)C(O)C([O-])=O.OCC1OB(O)OC1C(O)C(O)C([O-])=O SSKRIDIHZLFJCG-UHFFFAOYSA-L 0.000 description 2
- 235000013365 dairy product Nutrition 0.000 description 2
- 230000007812 deficiency Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 235000010270 methyl p-hydroxybenzoate Nutrition 0.000 description 2
- 239000004292 methyl p-hydroxybenzoate Substances 0.000 description 2
- 229960002216 methylparaben Drugs 0.000 description 2
- 238000007911 parenteral administration Methods 0.000 description 2
- 239000002244 precipitate Substances 0.000 description 2
- 230000009467 reduction Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000003381 stabilizer Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 231100000419 toxicity Toxicity 0.000 description 2
- 230000001988 toxicity Effects 0.000 description 2
- SPFMQWBKVUQXJV-BTVCFUMJSA-N (2r,3s,4r,5r)-2,3,4,5,6-pentahydroxyhexanal;hydrate Chemical compound O.OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C=O SPFMQWBKVUQXJV-BTVCFUMJSA-N 0.000 description 1
- VNEJPLLPMHBPNK-UHFFFAOYSA-N 2-(butylamino)propan-2-ylphosphonic acid Chemical group CCCCNC(C)(C)P(O)(O)=O VNEJPLLPMHBPNK-UHFFFAOYSA-N 0.000 description 1
- BHPQYMZQTOCNFJ-UHFFFAOYSA-N Calcium cation Chemical compound [Ca+2] BHPQYMZQTOCNFJ-UHFFFAOYSA-N 0.000 description 1
- 241001466804 Carnivora Species 0.000 description 1
- 206010010071 Coma Diseases 0.000 description 1
- 208000013038 Hypocalcemia Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 229910019142 PO4 Inorganic materials 0.000 description 1
- 241001494479 Pecora Species 0.000 description 1
- 206010073945 Perinatal stroke Diseases 0.000 description 1
- 239000005922 Phosphane Substances 0.000 description 1
- XYFCBTPGUUZFHI-UHFFFAOYSA-N Phosphine Chemical compound P XYFCBTPGUUZFHI-UHFFFAOYSA-N 0.000 description 1
- 230000004596 appetite loss Effects 0.000 description 1
- 239000008346 aqueous phase Substances 0.000 description 1
- 239000007864 aqueous solution Substances 0.000 description 1
- 229910001424 calcium ion Inorganic materials 0.000 description 1
- 244000309466 calf Species 0.000 description 1
- 235000019577 caloric intake Nutrition 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 206010061428 decreased appetite Diseases 0.000 description 1
- 230000001627 detrimental effect Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 229960000673 dextrose monohydrate Drugs 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical group [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 210000005069 ears Anatomy 0.000 description 1
- 239000000839 emulsion Substances 0.000 description 1
- 230000007613 environmental effect Effects 0.000 description 1
- 235000021321 essential mineral Nutrition 0.000 description 1
- 239000013020 final formulation Substances 0.000 description 1
- 239000008103 glucose Substances 0.000 description 1
- 230000000705 hypocalcaemia Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 230000006651 lactation Effects 0.000 description 1
- 231100001231 less toxic Toxicity 0.000 description 1
- 208000019017 loss of appetite Diseases 0.000 description 1
- 235000021266 loss of appetite Nutrition 0.000 description 1
- 229910001629 magnesium chloride Inorganic materials 0.000 description 1
- 238000007726 management method Methods 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 235000010755 mineral Nutrition 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 231100000252 nontoxic Toxicity 0.000 description 1
- 230000003000 nontoxic effect Effects 0.000 description 1
- 229940041672 oral gel Drugs 0.000 description 1
- 230000032696 parturition Effects 0.000 description 1
- 230000009984 peri-natal effect Effects 0.000 description 1
- 239000012071 phase Substances 0.000 description 1
- 229910000064 phosphane Inorganic materials 0.000 description 1
- 239000010452 phosphate Substances 0.000 description 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 description 1
- 235000007628 plant based diet Nutrition 0.000 description 1
- 238000001556 precipitation Methods 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000002689 soil Substances 0.000 description 1
- 238000012430 stability testing Methods 0.000 description 1
- 230000009469 supplementation Effects 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 231100000331 toxic Toxicity 0.000 description 1
- 230000002588 toxic effect Effects 0.000 description 1
- 231100000701 toxic element Toxicity 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K33/00—Medicinal preparations containing inorganic active ingredients
- A61K33/42—Phosphorus; Compounds thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/02—Nutrients, e.g. vitamins, minerals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
- A61P3/14—Drugs for disorders of the metabolism for electrolyte homeostasis for calcium homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Epidemiology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Inorganic Chemistry (AREA)
- Rheumatology (AREA)
- Nutrition Science (AREA)
- Endocrinology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
Description
a)少なくとも3つの異なるカルシウム塩、及び
b)糖の形態のエネルギー源
を含む注入可能な動物用組成物であって、
前記塩のうちの1つが糖酸カルシウムである
ことを特徴とする組成物が提供される。
a)少なくとも3つの異なるカルシウム塩、及び
b)糖の形態のエネルギー源
を含む注入可能な組成物を動物に投与するステップを含む、動物において乳熱を治療する方法であって、
前記塩のうちの1つが糖酸カルシウムである
ことを特徴とする方法が提供される。
ステップ1
・注射用水を清潔な製造容器中にロードし、85〜95℃まで加熱する。
ステップ2
・注射用水を第2の容器中にロードし、80〜90℃まで加熱する。
・メチルパラベンを第2の容器に加え、混合物を80〜90℃で維持する。
ステップ3
・次いで、ステップ2の注射用水及びメチルパラベン混合物を、ステップ1の注射用水を含有する第1の容器に加え、よく混合する。
・グルコン酸カルシウムをバルクに加え、混合物を85〜95℃で維持しながら、撹拌により溶解させる。次いで、糖酸カルシウムをバルクに加え、撹拌により溶解させる。混合物の温度を80〜85℃まで低下させ、維持する。
・次いで、デキストロース一水和物をバルクに加え、撹拌により溶解させ、続いて次亜リン酸マグネシウム及び塩化カルシウムを加える。バルクを、すべての構成成分が溶解するまで撹拌する。
・次いで、バルクを注射用水でバッチサイズの90%とし、次いで25〜30℃まで冷却する。冷却したら、注射用水でその体積とし、よく撹拌する。組成物のpHは、4.6〜5.1の間とするべきである。
試料の色は、透明な無色の溶液から暗褐色に変化した:
色の変化なし。このことは、相溶性が、試験されたホスホリルコラミンとカルシウム塩との間のものであったことを示している可能性がある。
試料の色は、透明な無色の溶液から暗褐色に変化した。
試料の色は、透明な無色の溶液から暗褐色に変化した。
試料は沈殿した。
安定剤としてプロピレングリコール
安定剤として糖酸カルシウム四水和物
Claims (10)
- a)少なくとも3つの異なるカルシウム塩、及び
b)糖の形態のエネルギー源
を含む、注入によって非ヒトにおける乳熱を治療するための組成物であって、
前記塩のうちの1つが糖酸カルシウムである
ことを特徴とする組成物。 - さらなるカルシウム塩が、ハロゲン化カルシウム、レブリン酸カルシウム、乳酸カルシウム、塩素酸カルシウム、酢酸カルシウム、プロピオン酸カルシウム、マンノン酸カルシウム及びグルコン酸カルシウムを含む群から選択される、請求項1に記載の組成物。
- 前記塩が、塩化カルシウム、グルコン酸カルシウム及び糖酸カルシウムである、請求項2に記載の組成物。
- 組成物中の合計溶解カルシウムが、10〜25g/Lの間である、請求項1から3のいずれか一項に記載の組成物。
- 0.5%w/vの糖酸カルシウムを含む、請求項1から4のいずれか一項に記載の組成物。
- 前記エネルギー源が、デキストロースを含む、請求項1から5のいずれか一項に記載の組成物。
- マグネシウム及び/又はリンをさらに含む、請求項1から6のいずれか一項に記載の組成物。
- 次亜リン酸マグネシウムを含む、請求項7に記載の組成物。
- 非ヒト動物において乳熱を治療する方法であって、前記非ヒト動物に、請求項1から8のいずれか一項に記載の注入可能な組成物を投与するステップを含む方法。
- 非ヒト動物が反芻動物である、請求項9に記載の方法。
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
NZ583602A NZ583602A (en) | 2010-02-26 | 2010-02-26 | Improved Calcium Formulation |
NZ583602 | 2010-02-26 | ||
PCT/NZ2010/000208 WO2011105912A1 (en) | 2010-02-26 | 2010-10-15 | Improved calcium formulation |
Publications (2)
Publication Number | Publication Date |
---|---|
JP2013520494A JP2013520494A (ja) | 2013-06-06 |
JP5674824B2 true JP5674824B2 (ja) | 2015-02-25 |
Family
ID=42358003
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
JP2012554958A Active JP5674824B2 (ja) | 2010-02-26 | 2010-10-15 | 改良されたカルシウム製剤 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP5674824B2 (ja) |
NZ (1) | NZ583602A (ja) |
WO (1) | WO2011105912A1 (ja) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN115707453A (zh) * | 2022-11-30 | 2023-02-21 | 常州兰陵制药有限公司 | 葡萄糖酸钙注射液及其制备方法 |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5576303A (en) * | 1993-03-16 | 1996-11-19 | Kabushiki Kaisha Hayashibara Seibutsu Kagaku Kenkyujo | Energy-supplementing saccharide source and its uses |
JP3631414B2 (ja) * | 2000-05-25 | 2005-03-23 | フジタ製薬株式会社 | 動物用経口カルシウム補給液剤及びその製造方法 |
DK1395128T4 (da) * | 2001-05-31 | 2011-10-24 | Abbott Lab | Syrestyret viskositetsfibersystem samt anvendelser deraf |
UA73005C2 (en) * | 2003-03-26 | 2005-05-16 | Close Joint Stock Company Phar | Method for producing calcium gluconate solution for injections |
UA73024C2 (en) * | 2003-07-21 | 2005-05-16 | Close Joint Stock Company Phar | 10 % solution of calcium gluconate for injections |
US7976833B2 (en) * | 2005-10-14 | 2011-07-12 | Aspen Biomedical Research, Llc | Ophthalmic surgical irrigating solutions containing hyaluronidase and method for preventing post-operative intraocular pressure increases |
-
2010
- 2010-02-26 NZ NZ583602A patent/NZ583602A/en unknown
- 2010-10-15 JP JP2012554958A patent/JP5674824B2/ja active Active
- 2010-10-15 WO PCT/NZ2010/000208 patent/WO2011105912A1/en active Application Filing
Also Published As
Publication number | Publication date |
---|---|
NZ583602A (en) | 2010-07-30 |
WO2011105912A1 (en) | 2011-09-01 |
JP2013520494A (ja) | 2013-06-06 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0619201A2 (pt) | composição alimentìcia, e, uso de uma composição | |
CN105685464A (zh) | 一种奶牛饲料添加剂及围产前期奶牛的饲养方法 | |
US8993001B2 (en) | Methods and compositions for treating feline hyperthyroidism | |
JP5674824B2 (ja) | 改良されたカルシウム製剤 | |
Ewuola et al. | Semen characteristics of rabbit bucks orally administered exogenous l-selenomethionine | |
EP2713767A1 (en) | Use of 25-hydroxy vitamin d3 to promote phosphorous utilisation in ruminants | |
EP3615041B1 (en) | Calcium binder for use in preventing stillbirth | |
JP6182015B2 (ja) | 家畜の繁殖成績改善剤 | |
KR20100112328A (ko) | 젤 형태의 사료 제품 및 그의 제조방법 | |
JP4918260B2 (ja) | 液体混合飼料およびその製造方法 | |
JP2008541767A5 (ja) | ||
CN102908354A (zh) | 一种布他磷注射液的制备方法 | |
AU677179B2 (en) | Pharmaceutical compositions and their use for treating zinc deficient disorders | |
AU2019101215A4 (en) | Compositions for Administration to Ruminant Animals | |
JP2008283893A (ja) | 家禽用コクシジウム感染抑制剤及びそれを用いたコクシジウム感染抑制方法 | |
Arthington et al. | Trace Mineral Nutrition of Grazing Beef Cattle. Animals 2021, 11, 2767 | |
Jiang et al. | Combined treatment with vitamin A and iron to prevent piglet anemia | |
JP2547400B2 (ja) | 動物用薬剤 | |
RU2130306C1 (ru) | Противоанемический и ростстимулирующий препарат для животных "гемовит-с" | |
West et al. | Hypomagnesaemic tetany in sheep | |
JP2023048213A (ja) | 水分補給剤 | |
Farmer | Factors affecting milk production and mammary development. | |
RU2302873C2 (ru) | Препарат для профилактики и лечения анемии, коррекции нарушений обмена веществ у сельскохозяйственных животных | |
NZ582005A (en) | Calcium and vitaminB12 based formulation for the treatment of milk fever in animals | |
JP2008546834A (ja) | セレンの豊富な食品の生産用の非経口投与セレノメチオニン |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20130319 |
|
A711 | Notification of change in applicant |
Free format text: JAPANESE INTERMEDIATE CODE: A712 Effective date: 20130531 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A821 Effective date: 20130531 |
|
A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20140421 |
|
A601 | Written request for extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A601 Effective date: 20140722 |
|
A602 | Written permission of extension of time |
Free format text: JAPANESE INTERMEDIATE CODE: A602 Effective date: 20140729 |
|
A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20140805 |
|
TRDD | Decision of grant or rejection written | ||
A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20141125 |
|
A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20141222 |
|
R150 | Certificate of patent or registration of utility model |
Ref document number: 5674824 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |